NCT07216105 2025-12-17
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Fate Therapeutics
Phase 1 Recruiting
Fate Therapeutics
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Sun Yat-sen University